comprehensive -WSS

comprehensive

author：leisure time 2025-09-27 12:53:42 - browse：5

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： 'Investigate these claims': UFO transparency at center of House hearing

leisure time

WSS

'Investigate these claims': UFO transparency at center of House hearing

Pregnant women don't need prenatal multivitamins, study concludes

Ozempic has benefits for kidney disease as well as diabetes

State of the Union pitch: Bigger Medicare drug price negotiations

The public health thinking behind the CDC’s new Covid guidance

Readout Newsletter: BridgeBio, Akero, and human embryo models

Wikipedia

comprehensive

explore

Apple is now the first public company to be valued at $3 trillion

STAT Report: Patient voices and perspectives

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

State of the Union pitch: Bigger Medicare drug price negotiations

Duchenne breakthrough therapy leaves behind pioneering families

What to watch for from Zogenix and Amicus clinical trials

Drug repurposing or repositioning? The language matters

Readout Newsletter: BridgeBio, Akero, and human embryo models

How one medical school became remarkably diverse

The untold story of TV’s first prescription drug ad

entertainment

State of the Union pitch: Bigger Medicare drug price negotiations

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Florida health officials providing scant details on measles cases

Pregnant women don't need prenatal multivitamins, study concludes

Longer MASH drug regimen improved liver, Akero study finds

Will the FTC rein in IQVIA's health data empire?

hotspot

leisure time

Wikipedia

knowledge